High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase deficiency on chronic glucocorticoid treatment

American Journal of Physiology - Endocrinology and Metabolism

Volumn 304, Issue 5, 2013, Pages

  Brunetti, Giacomina ^a   Faienza, Maria Felicia ^a   Piacente, Laura ^a   Ventura, Annamaria ^a   Oranger, Angela ^a   Carbone, Claudia ^a   Di Benedetto, Adriana ^a   Colaianni, Graziana ^a   Gigante, Margherita ^b   Mori, Giorgio ^b   Gesualdo, Loreto ^a   Colucci, Silvia ^a   Cavallo, Luciano ^a   Grano, Maria ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

21 hydroxylase deficiency patients; Dickkopf 1; Glucocorticoid induced osteoporosis; Glucocorticoids; Leukocytes

Indexed keywords

DEXAMETHASONE; DICKKOPF 1 PROTEIN; HYDROCORTISONE; OSTEOCLAST DIFFERENTIATION FACTOR;

ADOLESCENT; ARTICLE; BONE MASS; BONE REMODELING; BONE TURNOVER; CELL DIFFERENTIATION; CHILD; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKOCYTE; MALE; MONOCYTE; NEUTROPHIL; OSTEOBLAST; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; SERUM; STEROID 21 MONOOXYGENASE DEFICIENCY; T LYMPHOCYTE;

ADOLESCENT; ADRENAL HYPERPLASIA, CONGENITAL; ALKALINE PHOSPHATASE; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD14; ANTIGENS, CD2; BLOTTING, WESTERN; BONE DENSITY; CELL DIFFERENTIATION; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GLUCOCORTICOIDS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKOCYTES; MALE; MICROSCOPY, CONFOCAL; NEUTROPHILS; OSTEOBLASTS; RANK LIGAND; REAL-TIME POLYMERASE CHAIN REACTION; STEROID 21-HYDROXYLASE;

EID: 84874528855     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00535.2012     Document Type: Article

References (54)

1. Aicher A, Kollet O, Heeschen C, Liebner S, Urbich C, Ihling C, Orlandi A, Lapidot T, Zeiher AM, Dimmeler S. The Wnt antagonist Dickkopf-1 mobilizes vasculogenic progenitor cells via activation of the bone marrow endosteal stem cell niche. Circ Res 103: 796-803, 2008.
2. Cameron FJ, Kaimakci B, Byrt EA, Ebeling PR, Warne GL, Wark JD. Bone mineral density and body composition in congenital adrenal hyperplasia. J Clin Endocrinol Metab 80: 2238-2243, 1995.
3. Canalis E, Bilezikian JP, Angeli A, Giustina A. Perspectives on glucocorticoid-induced osteoporosis. Bone 34: 593-598, 2004.
4. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoidinduced osteoporosis: pathophysiology and therapy. Osteoporos Int 18: 1319-1328, 2007.
5. Christiansen P, Moolgard C, Muller J. Normal bone mineral content in young adults with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res 61: 133-136, 2004.
6. Colucci S, Brunetti G, Rizzi R, Zonno A, Mori G, Colaianni G, Del Prete D, Faccio R, Liso A, Capalbo S, Liso V, Zallone A, Grano M. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 104: 3722-3730, 2004.
7. Dalbeth N, Pool B, Smith T, Callon KE, Lobo M, Taylor WJ, Jones PB, Cornish J, McQueen FM. Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. Arthritis Res Ther 12: R164, 2010.
8. de Almeida Freire PO, de Lemos-Marini SH, Maciel-Guerra AT, Morcillo AM, Matias Baptista MT, de Mello MP, Guerra G Jr. Classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a cross-sectional study of factors involved in bone mineral density. J Bone Miner Metab 21: 396-401, 2003.
9. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13: 156-163, 2007.
10. Faienza MF, Brunetti G, Colucci S, Piacente L, Ciccarelli M, Giordani L, Del Vecchio GC, D'Amore M, Albanese L, Cavallo L, Grano M. Osteoclastogenesis in children with 21-hydroxylase deficiency on longterm glucocorticoid therapy: the role of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin imbalance. J Clin Endocrinol Metab 94: 2269-2276, 2009.
11. Fujita K, Janz S. Attenuation of WNT signaling by DKK-1 and-2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer 6: 71, 2007.
12. Girgis R, Winter JSD. The effects of glucocorticoid replacement therapy on growth, bone mineral density and bone turnover markers in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 82: 3926-3929, 1997.
13. Guo CY, Weetman AP, Eastel R. Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 45: 535-541, 1996.
14. Gussinyé M, Carrascosa A, Potau N, Enrubia M, Vicens-Calvet E, Ibáñez L, Yeste D. Bone mineral density in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia. Pediatrics 100: 671-674, 1997.
15. Hagenfeldt K, Martin Ritzén E, Ringertz H, Helleday J, Carlström K. Bone mass and body composition of adult women with congenital virilizing 21-hydroxylase deficiency after glucocorticoid treatment since infancy. Eur J Endocrinol 143: 667-671, 2000.
16. Jaaskelainen J, Voutilainen R. Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 45: 707-713, 1996.
17. Jang WG, Kim EJ, Kim DK, Ryoo HM, Lee KB, Kim SH, Choi HS, Koh JT. BMP2 protein regulates osteocalcin expression via Runx2-mediated Atf6 gene transcription. J Biol Chem 287: 905-915, 2012.
18. Joint LWPES/ESPE CAH Working Group. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab 87: 4048-4053, 2002.
19. Kanis JA, Glüer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 11: 192-202, 2000.
20. King JA, Wisniewski AB, Bankowski BJ, Carson KA, Zacur HA, Migeon CJ. Long-term corticosteroid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 91: 865-869, 2006.
21. Koch S, Nava P, Addis C, Kim W, Denning TL, Li L, Parkos CA, Nusrat A. The Wnt antagonist Dkk1 regulates intestinal epithelial homeostasis and wound repair. Gastroenterology 141: 259-268, 2011.
22. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402: 304-309, 1999.
23. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest 116: 1202-1209, 2006.
24. Lajic S, Nordenström A, Hirvikoski T. Long-term outcome of prenatal dexamethasone treatment of 21-hydroxylase deficiency. Endocr Dev 20: 96-105, 2011.
25. Lee N, Smolarz AJ, Olson S, David O, Reiser J, Kutner R, Daw NC, Prockop DJ, Horwitz EM, Gregory CA. A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. Br J Cancer 97: 1552-1559, 2007.
26. Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, Shalhoub V, Ominsky MS, Zhu Ke H, Li X, Richards WG. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39: 754-766, 2006.
27. Mak W, Shao X, Dunstan CR, Seibel MJ, Zhou H. Biphasic glucocorticoid-dependent regulation of Wnt expression and its inhibitors in mature osteoblastic cells. Calcif Tissue Int 85: 538-545, 2009.
28. Marshall MJ, Evans SF, Sharp CA, Powell DE, McCarthy HS, Davie MW. Increased circulating Dickkopf-1 in Paget's disease of bone. Clin Biochem 42: 965-969, 2009.
29. Mazziotti G, Porcelli T, Bianchi A, Cimino V, Patelli I, Mejia C, Fusco A, Giampietro A, De Marinis L, Giustina A. Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur J Endocrinol 163: 15-20, 2010.
30. Mora S, Saggion F, Russo G, Weber G, Bellini A, Prinster C, Chiumello G. Bone density in young patients with congenital adrenal hyperplasia. Bone 18: 337-340, 1996.
31. Morvan F, Boulukos K, Clément-Lacroix P, Roman Roman S, Suc-Royer I, Vayssière B, Ammann P, Martin P, Pinho S, Pognonec P, Mollat P, Niehrs C, Baron R, Rawadi G. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21: 934-945, 2006.
32. Naot D, Bava U, Matthews B, Callon KE, Gamble GD, Black M, Song S, Pitto RP, Cundy T, Cornish J, Reid IR. Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone. J Bone Miner Res 22: 298-309, 2007.
33. New MI. An update of congenital adrenal hyperplasia. Ann NY Acad Sci 1038: 14-43, 2004.
34. Ohnaka K, Taniguchi H, Kawate H, Nawata H, Takayanagi R. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 318: 259-264, 2004.
35. Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 329: 177-181, 2005.
36. Paganini C, Radetti G, Livieri C, Braga V, Migliavacca D, Adami S. Height, bone mineral density, and bone markers in congenital adrenal hyperplasia. Horm Res 54: 164-168, 2000.
37. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
38. Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J, Barlogie B, Shaughnessy JD Jr. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 112: 196-207, 2008.
39. Rippo MR, Villanova F, Tomassoni Ardori F, Graciotti L, Amatori S, Manzotti S, Fanelli M, Gigante A, Procopio A. Dexamethasone affects Fas-and serum deprivation-induced cell death of human osteoblastic cells through survivin regulation. Int J Immunopathol Pharmacol 23: 1153-1165, 2010.
40. Rivkees SA, Stephenson K. Low-dose dexamethasone therapy from infancy of virilizing congenital adrenal hyperplasia. Int J Pediatr Endocrinol 2009: 274682, 2009.
41. Roato I, D'Amelio P, Gorassini E, Grimaldi A, Bonello L, Fiori C, Delsedime L, Tizzani A, De Libero A, Isaia G, Ferracini R. Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS One 3: e3627, 2008.
42. Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, Erickson RL, MacDougald OA. Inhibition of adipogenesis by Wnt signaling. Science 289: 950-953, 2000.
43. Schaeffer TL, Tryggestad JB, Mallappa A, Hanna AE, Krishnan S, Chernausek SD, Chalmers LJ, Reiner WG, Kropp BP, Wisniewski AB. An Evidence-Based Model of Multidisciplinary Care for Patients and Families Affected by Classical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency. Int J Pediatr Endocrinol 2010: 692439, 2010.
44. Sciannamblo M, Russo G, Cuccato D, Chiumello G, Mora S. Reduced bone mineral density and increased bone metabolism rate in young adult patients with 21-hydroxylase. J Clin Endocrinol Metab 91: 4453-4458, 2006.
45. Senolt L, Hulejova H, Krystufkova O, Forejtova S, Andres Cerezo L, Gatterova J, Pavelka K, Vencovsky J. Low circulating Dickkopf-1 and its link with severity of spinal involvement in diffuse idiopathic skeletal hyperostosis. Ann Rheum Dis 71: 71-74, 2012.
46. Speiser PW, New MI. Increased bone mineral density in congenital adrenal hyperplasia (Abstract). Pediatr Res 33: S81, 1993.
47. Stikkelbroeck NM, Oyen WJ, van der Wilt GJ, Hermus AR, Otten BJ. Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 88: 1036-1042, 2003.
48. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7: 292-304, 2007.
49. Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 135: 688-692, 2006.
50. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2483-2494, 2003.
51. Wang FS, Ko JY, Yeh DW, Ke HC, Wu HL. Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 149: 1793-1801, 2008.
52. Wang SY, Liu YY, Ye H, Guo JP, Li R, Liu X, Li ZG. Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. J Rheumatol 38: 821-827, 2001.
53. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoidtreated mice. Arthritis Rheum 58:1674-1686, 2008.
54. Zelissen PM, Croughs RJ, van Rijk PP, Raymakers JA. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 120: 207-210, 1994.